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Abstract   
Background: Phenylketonuria (PKU) is a well-known rare disease which is included in the 
neonatal screening of many countries. Therefore there are few published data on the admissions 
and cost in Spain. 
Objective: To assess the number of admissions and economic burden of PKU in Spain. 
Methods: PKU patients were identified from a Spanish database containing data from public and 
private healthcare centres from 1997 to 2015. The parameters obtained were: characteristics of 
the patients, type of admissions, readmissions, discharge, length of stay, medical service, annual 
number of visits, annual number of patients, visit associated costs and patient associated costs.  
Results: 594 PKU patients were identified: 48.32% were males with a mean (SD) age of 4.50 
(10.23) years. The hospital admissions were divided into emergency visits (55.94%) and 
scheduled visits (43.92%). Most of the discharges were at home (98.86%). The mean (SD) 
duration of stay was 4.04(4.98) days. The prevalence rate decreased from 0.27‰ to 0.10‰ from 
2007 to 2015. Finally, the mean cost per visit increased from € 1,600 to € 3,700, and the mean 
cost per patient from € 1,800 to € 4,200 from 2007 to 2015. 
Conclusions: The access to economic and social data about PKU in Spain has been updated. The 
number of admissions in Spain between 2007 and 2015 and healthcare costs between 1997 and 
2015 was calculated. There were 24 admissions due to PKU diagnostic in 2015 and the mean 
healthcare cost per patient was € 4,239.32. This information can help to adapt and improve the 
healthcare system to the actual situation. 
 
Key points: The available data for economic burden and number of admissions of PKU is updated 






Phenylketonuria (PKU) is a rare and autosomal recessive inborn error of Phenylalanine (Phe) 
metabolism caused by variants in the gene encoding Phenylalanine Hydroxylase (PAH) [1]. It 
causes a deficiency of PAH, which is the enzyme that catalyses the hydroxylation of Phe to 
tyrosine [2]. An accumulation of Phe in blood causes neurotoxic effects that can lead to 
irreversible intellectual disability, microcephaly, motor deficits, eczematous rash, autism, 
seizures, developmental problems, aberrant behaviour and psychiatric symptoms [1]. 
A worldwide prevalence rate of 0.04-0.1‰ [3] has been estimated, which varies depending on 
the geographic region (high rate in Ireland (0.22‰) or Turkey (0.38‰) and very low rate in 
Finland (0.005‰) [1]) and the ethnic groups (PKU is more common in Chinese people (0.06‰) 
than in the Africans (0.01‰) [2,4]). The main risks factors associated to PKU are the 
consanguinity among parents since it is an autosomal recessive disease [5]. Thus, the 
consanguinity along with the fact that PKU is a rare disease and a wrong detection can lead to a 
great change in the prevalence rate, leads to a variable prevalence rate among populations.  
PKU is one of the universal diseases included in the neonatal screening that meets all the 
screening criteria and justifies all the associated costs [6]. In Spain, it was the first disease 
included in the national neonatal screening in 1968 [7]. The early detection of this disease and 
the treatment at birth prevents neurocognitive damage. The primary treatment consists in a 
Phe-reduced diet and/or the use of sapropterin (also called BH4) [8], a cofactor that reduces the 
Phe blood levels.  
However, there are different parameters and factors regarding this disease that have not been 
studied yet. In order to include a disease in the neonatal screening, and from the economic point 
of view, it must be demonstrated that the costs associated with diagnosing all newborns are less 
than the costs associated with diagnosing and treating those affected later on [9]. Other clinical 
criteria that PKU fulfil is a promptly and accessible effectiveness treatment [10]. Nevertheless, 
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there are few studies on economic burden of PKU. So, there is an obvious need to determine 
the economic impact of PKU from the National Health Service perspective.  
The number of PKU admissions and costs associated to treat PKU patients in Spain during 18 
years were studied. All the necessary information was obtained from a national claims database 




This retrospective study was based on a sample extracted from the Spanish claims database 
Minimum Basic Data Set (Conjunto Mínimo Básico de Datos (CMBD)) [11]. The CMBD contains 
data from 1997 to 2015 and includes registers of 313 public hospitals and 192 private hospitals 
(data from 2004). The database contains patient characteristics (age, gender, region of 
residence, type of reimbursement), hospitalization diagnosis, comorbidities and complications, 
therapeutic and diagnostic procedures, length of stay, type of admission and discharge, 
diagnosis-related group (DRG) for each episode and cost per DRG.  Both diagnostics and 
procedures are codified by the International Classification of Diseases, Ninth Revision (ICD-9) 
used also to assign the DRG associated with the hospital stay. 
Study population   
The study included all the patients for whom a hospitalization for PKU (ICD-9 code 270.1 
documented as a primary diagnosis) was identified in the CMBD database between 1st January 
1997, and 31st December 2015. This hospitalisation was considered to be the index event. For 
patients hospitalised for PKU more than once over the study period, the earliest event was 
considered as the index event. For each eligible patient, information was extracted on 
demographics (gender and age at the time of index hospitalisation), hospitalisation for PKU 
(admission, duration, discharge, readmission and medical service), comorbidities, procedures 




Data presentation is mainly descriptive, and no specific hypothesis was tested. Categorical data 
are presented as frequency counts and percentages and continuous data as mean values plus 
standard deviation (SD).   
The analysable population consisted of all patients presenting PKU diagnosis during the study 
period. Study variables were described in the total patient population. All PKU diagnosis 
occurring during the study period was considered for the estimation of incidence. The annual 
number of patients and visits and visit and patient associated costs were also estimated.  
Patient characteristics and most common comorbidities have also been studied. 
All statistical analyses were performed using Microsoft Excel© Professional Plus 2010 (Microsoft 
Corporation, Redmond, WA, USA).   
Ethical considerations 
Since this was a study of an anonymised database and had no influence on patient care, ethics 
committee approval was not required. 
 
RESULTS 
Characteristics of patients identified in the database 
During the study period 1997-2015, 699 PKU-related visits were identified in the CMBD 
database, which corresponded to a total of 594 patients with PKU. Around half of the identified 
patients were males (N=287; 48.32%) with an average age of 4.76 (SD=12.22) years.  The 
identified females (N=307; 51.68%) had an average age of 4.25 (SD=7.91) years (Table 1).  
The most frequent comorbidities, which affect more than 1% of identified in PKU patients were: 
Escherichia Coli infection (1.43%), epilepsy (1.29%), obesity (1.14%) and urinary tract infection 
(1.00%) (Table 2). 
The hospitalization admissions for PKU patients were divided into emergency visits (55.94%) and 
scheduled visits (43.92%). Only 4.43% of the PKU patients were readmitted before 30 days after 
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discharge. The mean (SD) length of hospital stay was 4.04 (4.98) days. Finally the majority of 
patients were discharged home (98.86%). More than half of the identified patients were 
attended by the paediatrics service (69.45%) (Table 3).  
Healthcare resources 
The number of admissions, number of patients and costs were assessed over the study period.  
The number of admissions per year ranges between 13 and 88 while the number of patients per 
year varies from 11 to 78. Both, number of admissions and patients, increased from 1997 to 
2004 and then started to decrease until 2015 (Figure 1). Thus, the number of admissions per 
patient per year ranges between 1.09 and 1.44, with a mean of 1.18 admissions per patient 
annually.  
Finally, the mean cost per visit increased from € 1,064.91 in 1999 to € 3,709.40 in 2015. The 
mean cost per patient increased from € 1,818.90 to € 4,239.32 in the same period (Table 4).   
 
DISCUSSION 
Characteristics of patients identified in the database  
In this study, characteristics of the identified patients have been studied. In comparison with 
other studies about PKU patients carried out previously [12,13], we can determine that there is 
no difference in PKU prevalence between males and females. The early diagnose of this disease, 
which has been stated to be diagnose at a mean age of 4.5 years by the paediatrics service, is 
mainly due to the inclusion of PKU in the neonatal screening in Spain.   
Primary PKU treatment is the dietary restriction of the amino acid phenylalanine [14], thus most 
of the controls and medical problems take place during childhood. With this treatment PKU is 





In this study, the number of admissions has been assessed over the study period. The number 
of admissions per year ranges between 13 and 88 while the number of admissions per patient 
per year ranges between 1.09 and 1.44, with a mean of 1.18 admissions per patient annually. A 
published study [15] assessed the costs and consequences of managing PKU over the first 36 
years of life. This study has estimated the healthcare resource use over the 36 years. According 
with the results, patients had a mean 12 general practitioner visits per year and one hospital 
outpatient visit annually. The results obtained in our study regarding hospital outpatient visits 
are similar to those obtained in the previously published study.  
Healthcare costs 
A published study [16] analysed the household financial burden associated to PKU in China in 
2014. It was based on a questionnaire conducted to the parents and caregivers at the China-
Japan Friendship Hospital. The mean (SD) of medical costs, including medical examination and 
medical rehabilitation) was $1612.4 ($6383.2) per year and the mean (SD) of non-medical cost, 
including Phe-free food and accommodation and transport for medical treatment, was $4221.2 
($2135.5) per year. An analysis performed in United Kingdom (UK) in 2013 [15] quantified the 
associated costs of managing during 36 years a PKU patient. It was based on a computer model 
derived from a national database. The mean medical cost for a patient who followed the Phe-
diet was £149,374, taking into account amino acids supplements, foods and drugs, medical visits, 
hospital admissions, laboratory tests and diagnostic procedures, which corresponds to 
£4,149.28 per year. For the patients who did not follow the diet, the mean medical cost was 
£21,367, which corresponds to £593.53 per year. Other cases were studied as patients who 
discontinued the diet and patients who discontinued and then restarted it.  
As far as authors know, some other economic and social analyses on PKU patients have been 
performed: one performed in UK [17] and one in the Netherlands [18], that were also based on 
questionnaires that do not calculate medical costs, and one performed in seven European 
countries [19], based on databases that reflects the quality of life of these patients.  
8 
 
In our study, the economic results obtained refer to the healthcare costs per year and were 
associated to the DRG assigned to each hospitalization. Therefore, it is not possible to establish 
a relationship between the obtained results in China and the ones of this study since the 
methodology used to obtain the costs cannot be compared. In addition, the medical policies and 
healthcare system of China have nothing to do with the healthcare system in Spain. Regarding 
the results for UK, it is also not possible to make a direct comparison of the results because the 
methodology employed in both studies is completely different. Nevertheless, the results 
obtained in all the cases, except for the patients in the UK that did not follow the diet (they are 
patients that are not attending hospitals or healthcare centres so their medical expenditures are 
low), are similar, which gives sense to our results. 
This study presents also some limitations. The first limitation is related with the source of 
information: all the calculations were performed assuming that all the PKU patients in Spain 
were included in the database. The second limitation is related with costs. The only costs 
considered in this study were the healthcare or direct costs because the costs were calculated 
by using the DRG associated to the main diagnosis. This cost is the representation of the mean 
cost of being hospitalized in Spain with a principal diagnosis of PKU so it is a generalization of a 
specific situation. Moreover, this DRG does not take into account secondary diagnoses, the age 
of the patient or the length of stay, which can completely modify the cost. Finally, the last 
limitation is related with the price of money fluctuations. Even though, this is considered in the 
DRG associated costs (the same DRG have different cost depending on the year), the money 
fluctuations between 1997 and 2015 were not considered. Therefore, it is not totally realistic to 
compare the costs of the different years.  
CONCLUSIONS 
In conclusion, the number of admissions in Spain between 2007 and 2015 and healthcare costs 
between 1997 and 2015 was calculated. There were 24 admissions related to PKU in 2015, with  
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admission per patient per year rate of 1.14. Finally,  the mean healthcare cost per patient was € 
4,239.32.  
Knowing the economic and social impact of rare diseases highlights the importance to develop 
this type of studies in every country. This would help to adapt and improve each healthcare 
system to take into consideration rare diseases. 
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Table 1: Phenylketonuria patient’s characteristics 
 All patients Male Female 
Number of patients (%) 594 (100%) 287 (48.32%) 307 (51.68%) 
Age    
Mean   4.50 years 4.76 years 4.25 years 
SD  10.23 years 12.22 years 7.91 years 
Maximum  111 years 111 years 40 years 
Minimum  0 years 0 years 0 years 
 
Table 2: Main comorbidities of phenylketonuria disease 
IDC-9 code Description Visits 
041.4 Escherichia Coli infection 10 (1.43%) 
345.90 Epilepsy  9 (1.29%) 
278.00 Obesity  8 (1.14%) 
599.00 Urinary tract infection 7 (1.00%) 
 
Table 3: Type of admissions, readmissions and discharged of phenylketonuria patients 
 Visits % 
Admissions   
Emergency 391 55.94% 
Scheduled 307 43.92% 
Others 1 0.14% 
Readmissions   
New episode 668 95.57% 
Readmission 31 4.43% 
Discharge   
Home 691 98.85% 
Other hospitals 5 0.72% 
Voluntary 2 0.29% 
Others 1 0.14% 
Medical service   
Paediatrics 291 69.45% 
Digestive 45 10.74% 
Neonatology 36 8.59% 





Table 4: Visits and patients per year and cost related to phenylketonuria disease 
 Total costs (€) Mean cost per visit (€) 
Mean cost per patient 
(€) 
1999 € 27,283.54 € 1,064.91 € 1,818.90 
2000 € 47,736.13 € 1,646.07 € 2,075.48 
2001 € 36,599.01 € 1,742.81 € 2,033.28 
2002 € 53,718.20 € 2,066.08 € 2,984.34 
2003 € 150,394.84 € 2,387.16 € 2,592.95 
2004 € 206,737.16 € 2,349.29 € 2,650.47 
2005 € 126,742.30 € 2,437.35 € 2,880.51 
2006 € 117,847.58 € 2,223.54 € 2,507.40 
2007 € 94,249.84 € 2,772.05 € 3,769.99 
2008 € 107,079.35 € 2,611.69 € 3,059.41 
2009 € 89,098.22 € 2,474.95 € 2,699.95 
2010 € 114,139.53 € 3,170.54 € 3,681.92 
2011 € 135,785.29 € 3,311.84 € 3,993.69 
2012 € 115,194.12 € 3,031.42 € 3,715.94 
2013 € 128,039.76 € 3,879.99 € 5,121.59 
2014 € 103,545.63 € 3,340.18 € 3,835.02 
2015 € 89,025.65 € 3,709.40 € 4,239.32 
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